Anti–coronavirus disease 2019 (COVID‐19) targets and mechanisms of puerarin

Qin, Xingyue; Huang, Chen; Wu, Ka; Liu, Yu; Xiao, Liang; Su, Min; Li, Rong

doi:10.1111/jcmm.16117

Cited by 43 publications

(35 citation statements)

References 35 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, a meta-analysis showed that EGFR is involved in pathological effects on the COVID-19 inflammatory process [ 39 ]. A drug discovery study demonstrated that the anti-COVID-19 action of puerarin was associated with the suppression of oxidative stress and inflammatory cascades through the induction of EGFR [ 40 ]. In addition to the pharmaceutical targets, the mechanisms underlying the effect of biochanin A were discovered using pathway analysis.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19

Qin

Guo

et al. 2021

Bioengineered

Self Cite

View full text Add to dashboard Cite

Severe mortality due to the COVID-19 pandemic resulted from the lack of effective treatment. Although COVID-19 vaccines are available, their side effects have become a challenge for clinical use in patients with chronic diseases, especially cancer patients. In the current report, we applied network pharmacology and systematic bioinformatics to explore the use of biochanin A in patients with colorectal cancer (CRC) and COVID-19 infection. Using the network pharmacology approach, we identified two clusters of genes involved in immune response ( IL1A, IL2 , and IL6R ) and cell proliferation ( CCND1, PPARG , and EGFR ) mediated by biochanin A in CRC/COVID-19 condition. The functional analysis of these two gene clusters further illustrated the effects of biochanin A on interleukin-6 production and cytokine-cytokine receptor interaction in CRC/COVID-19 pathology. In addition, pathway analysis demonstrated the control of PI3K-Akt and JAK-STAT signaling pathways by biochanin A in the treatment of CRC/COVID-19. The findings of this study provide a therapeutic option for combination therapy against COVID-19 infection in CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19

Qin

Guo

et al. 2021

Bioengineered

Self Cite

View full text Add to dashboard Cite

show abstract

“…Molecular docking methodology was effective strategy to identify the binding ability of PA with core targets in CG. More computational procedures could be referenced as previous description 20 …”

Section: Methodsmentioning

confidence: 99%

Bioinformatics and experimental findings reveal the therapeutic actions and targets of pachymic acid against cystitis glandularis

Shi

Liang

et al. 2021

BioFactors

View full text Add to dashboard Cite

Pachymic acid (PA), a bioactive ingredient isolated from Poria cocos Wolf, is reported with potential benefits of anti‐inflammatory, anti‐oxidative actions. It is reasoned that PA may play the potential benefits against cystitis glandularis (CG), an inflammation of the bladder tissue. In this study, we aimed to apply the network pharmacology and molecular docking analyses to reveal concrete anti‐CG targets and mechanisms of PA, and then the bioinformatic findings were verified by using clinical and animal samples. The methodological data from network pharmacology approach showed that 303 and 243 reporting targets of CG and PA, and other 31 shared targets of CG and PA were identified. Subsequently, all top targets of PA against CG were screened out, including cyclooxygenase‐2, epidermal growth factor receptor, tumor antigen p53 (TP53), tumor necrosis factor‐alpha (TNF), interleukin‐1 (IL‐1) beta, proto‐oncogene c‐jun. Molecular docking data demonstrated that PA exerted potent bonding capacities with TNF, TP53 proteins in CG. In human study, the findings suggested that overactivated TNF‐α expression and suppressed TP53 activation were detected in CG samples. In animal study, PA‐treated mice showed reduced intravesical IL‐1, IL‐6 levels, and lactate dehydrogenase content, downregulated TNF‐α and upregulated TP53 proteins in bladder samples. Taken together, our bioinformatics and experimental findings identify the key anti‐CG biotargets and mechanisms of PA. More markedly, these pivotal pharmacological targets of PA against CG have been screened out and verified by using computational and experimental analyses.

show abstract

“…Furthermore, liver cancer target genes were attained through retrieving in GeneCard, OMIM, Oncodb.hcc databases [ 18 ]. All overlapping genes of oxyresveratrol and liver cancer were identified and exhibited by using Venn diagram analysis [ 19 , 20 ].…”

Section: Methodsmentioning

confidence: 99%

Exploring anti-liver cancer targets and mechanisms of oxyresveratrol: in silico and verified findings

et al. 2021

View full text Add to dashboard Cite

The aim of current study was to exhume the potential targets and molecular mechanisms of oxyresveratrol, a structurally re-constructed resveratrol, for treating liver cancer through bioinformatics investigation and experimentative validation. To start with, the network pharmacology approach and molecular docking technology were used to uncover all candidate targets of oxyresveratrol to treat liver cancer, accompanied with identified anti-liver cancer targets including estrogen receptor 1 (ESR1), epidermal growth factor receptor (EGFR). In addition, more pharmacological mechanisms of oxyresveratrol against liver cancer were revealed in details. In experimental verification, the clinical samples of liver cancer showed elevated ESR1, EGFR mRNA expressions. The in-vitro data indicated that intracellular contents of ESR1, EGFR mRNAs in oxyresveratrol-treated liver cancer cells were reduced. Taken together, the bioinformatics and validated findings have highlighted detailed pharmacological targets and molecular mechanisms of oxyresveratrol for treating liver cancer. Following with experimental verification, the identified genes of ESR1, EGFR may function as potential screening anti-liver cancer markers.

show abstract

Anti–coronavirus disease 2019 (COVID‐19) targets and mechanisms of puerarin

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 43 publications

References 35 publications

Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19

Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19

Bioinformatics and experimental findings reveal the therapeutic actions and targets of pachymic acid against cystitis glandularis

Exploring anti-liver cancer targets and mechanisms of oxyresveratrol: in silico and verified findings

Contact Info

Product

Resources

About